Assembly Biosciences Inc (NASDAQ:ASMB) – Analysts at Jefferies Group issued their Q2 2018 EPS estimates for Assembly Biosciences in a research note issued to investors on Thursday. Jefferies Group analyst M. Yee anticipates that the biopharmaceutical company will post earnings of ($0.77) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $75.00 target price on the stock.
Several other research analysts have also weighed in on ASMB. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Wednesday, November 15th. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, B. Riley started coverage on Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $54.25.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its stake in Assembly Biosciences by 19.6% in the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after purchasing an additional 347,025 shares during the period. BlackRock Inc. boosted its stake in Assembly Biosciences by 19.6% in the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock valued at $48,784,000 after purchasing an additional 176,976 shares during the period. Vanguard Group Inc. boosted its stake in Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after purchasing an additional 107,065 shares during the period. Perceptive Advisors LLC boosted its stake in Assembly Biosciences by 21.5% in the 4th quarter. Perceptive Advisors LLC now owns 536,626 shares of the biopharmaceutical company’s stock valued at $24,282,000 after purchasing an additional 94,793 shares during the period. Finally, Rock Springs Capital Management LP boosted its stake in Assembly Biosciences by 15.4% in the 4th quarter. Rock Springs Capital Management LP now owns 450,000 shares of the biopharmaceutical company’s stock valued at $20,363,000 after purchasing an additional 60,000 shares during the period. Institutional investors and hedge funds own 77.26% of the company’s stock.
In related news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $46.86, for a total value of $46,860.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $148,270 over the last 90 days. 19.60% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Equities Analysts Offer Predictions for Assembly Biosciences Inc’s Q2 2018 Earnings (ASMB)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2018/03/14/equities-analysts-offer-predictions-for-assembly-biosciences-incs-q2-2018-earnings-asmb.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.